Stock CASI CASI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Delayed Nasdaq
Other stock markets
 09:15:44 02/05/2024 pm IST 		5-day change 1st Jan Change
2.475 USD +3.56% Intraday chart for CASI Pharmaceuticals, Inc. +7.61% -65.43%
28/03 CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
05/03 Top Midday Gainers MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Top Midday Gainers
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday
Top Premarket Gainers
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd
Casi Pharmaceuticals Announces First Dose of Folotyn in China
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CASI Pharmaceuticals Acquires Intellectual Property Rights to Cleave Therapeutics' Drug Candidate CB-5339
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CASI, Cleave Say China Drug Regulator Approves Clinical Trial Application for CB-5339 in Patients With Multiple Myeloma
CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CASI Pharmaceuticals, BioInvent Dose First Patient in Trial of Combination Treatment for Non-Hodgkin's Lymphoma
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CASI Stock
  4. News CASI Pharmaceuticals, Inc.
  5. Other languages